Pasithea Therapeutics (KTTA)10% owner bought ~$53K

~$53K

Approx. value · 100K sh @ $0.53

3.84M

Holds after · shares reported

Traded

Jun 17, 2026

Filed

Jun 22, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. May 1, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On May 4, 2026, Pasithea Therapeutics Corp. (the “Company”) announced the appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer of the Company, effective May 1, 2026.”
2. Jun 17, 2026 · this disclosureInsider · Their first buy on record10% owner purchased ~$53K of KTTA shares in the open market

What came next

1. Aug 20, 2026Company filing · Form 8-K · Listing noticeReceived a notice from its stock exchange“As previously reported, on February 20, 2026, Pasithea Therapeutics Corp. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), for the prior 30 consecutive business days, the Company was not in compliance…”

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Pasithea Therapeutics

For Pasithea Therapeutics, OQRO holds 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its KTTA page.

Other recent filings by Coastlands Capital LP, 10% owner

• SEC Form 4 at Adial Pharmaceuticals (ADIL)Jul 17, 2026
• SEC Form 4 at Adial Pharmaceuticals (ADIL)Jul 17, 2026
• SEC Form 4 at Adial Pharmaceuticals (ADIL)Jul 13, 2026
• SEC Form 4 at Adial Pharmaceuticals (ADIL)Jul 13, 2026
• SEC Form 4 at Adial Pharmaceuticals (ADIL)Jul 1, 2026

The full history of Coastlands Capital LP, 10% owner is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Pasithea Therapeutics

• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRMay 15, 2026
• SEC Form 4Dec 1, 2025
• SEC Form 4Dec 1, 2025
• SEC Form 4Dec 1, 2025
• SEC Form 4May 15, 2025

Everything OQRO holds on this company is on its KTTA page.